Group 1: Market Overview - In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due to concerns about Robert F. Kennedy's nomination for Health and Human Services Secretary [1] - In 2025, the technology sector has disappointed investors, while healthcare stocks have led the U.S. market higher, with Gilead Sciences being the best performing member of the Nasdaq-100 index as of March 9, achieving a year-to-date return of 27% [1] Group 2: Company Performance - AppLovin reported a 44% increase in revenue to $1.3 billion in Q4, with non-GAAP net income more than tripling, but the stock has fallen 47% from its high this year due to negative reports from short sellers [3] - Palantir consistently beat Wall Street's expectations with its financial results last year, but the stock has fallen 32% from its high this year due to concerns about insider selling and possible Pentagon budget cuts [4] - Nvidia, the market leader in data center GPUs, has seen its stock fall 25% from its high this year due to concerns about the sustainability of AI infrastructure spending and export restrictions [5] Group 3: Analyst Sentiment - Despite recent declines, Wall Street remains predominantly bullish on AppLovin, Palantir, and Nvidia, with median target prices implying substantial upside for shareholders [6] - AppLovin's median target price of $555 per share implies 132% upside from its current share price of $239, Palantir's median target price of $97 per share implies 22% upside from its current share price of $79, and Nvidia's median target price of $175 per share implies 65% upside from its current share price of $106 [10] Group 4: Gilead Sciences - Gilead Sciences is a pharmaceutical company with a strong presence in the HIV and oncology markets, known for developing the first once-daily tablet for HIV treatment and receiving approval for a pre-exposure prophylaxis (PrEP) HIV medication [7] - Gilead reported Q4 financial results that beat Wall Street expectations, with revenue increasing 6% to $7.6 billion and non-GAAP net income increasing 10% to $1.90 per diluted share [8] - Gilead anticipates regulatory approval of twice-yearly lenacapavir injections for HIV pre-exposure prophylaxis in the U.S. and updates from two phase-3 clinical trials involving Trodelvy, which has been designated as a breakthrough therapy by the FDA [9][12] - Gilead shares trade at a reasonable price, with Wall Street expecting adjusted earnings to increase at 32% annually over the next two years, making the current price-to-earnings (PE) multiple of 25 look fair [13]

Financial Data and Key Metrics Changes - Total investment income for Q4 2024 was $34.9 million, up 16.9% from $29.8 million in the prior year period [34] - Net investment income for Q4 2024 was $14.8 million or $0.45 per share, compared to $15.4 million or $0.58 per share for the same period last year [35] - NAV per share at the end of Q4 was $16.50, down from $16.61 at the end of Q3 2024 [36] Business Line Data and Key Metrics Changes - The total investment portfolio as of December 31, 2024, had a fair value of approximately $1.41 billion, reflecting a small increase of approximately 1.2% from $1.39 billion at the end of Q3 2024 [25] - New private credit loans comprised 17% of overall new investments, funded at a weighted average spread of 489 basis points over the reference rate [32] Market Data and Key Metrics Changes - The company reported an 11.6% yield as of December 31, 2024, which remains highly attractive by historical measures [23] - The weighted average total yield to maturity of debt and income-producing securities at fair value was 10.65% [30] Company Strategy and Development Direction - The company aims to maintain a competitive dividend yield while being disciplined in capital deployment for better opportunities in the future [40] - The investment philosophy focuses on delivering attractive risk-adjusted returns through a diversified portfolio that spans both liquid bank loans and private credit loans [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to navigate the evolving macroeconomic backdrop, emphasizing the importance of floating rate senior secured credit in the current environment [16][17] - The company is positioned to act quickly and efficiently when attractive opportunities arise, despite ongoing uncertainty around interest rates [12][20] Other Important Information - The Board and management team recalibrated the base dividend to $0.36 beginning in Q1 2025 to support NAV stability [28] - The company has a stock repurchase plan approved by the Board, allowing for the acquisition of up to $20 million of PSBD stock [39] Q&A Session Summary Question: Outlook for dividends and sustainability - Management indicated that the new dividend level was set conservatively based on various scenarios and the current deal environment [44][46] Question: Potential investment sales or prepayments outlook - Management noted elevated repayment and refinancing activity in Q4, with expectations for continued refinancing rather than new M&A activity in the near term [48][50] Question: Impact of cautious deal opportunities on leverage - Management confirmed that while they would not actively reduce leverage, they would be patient in waiting for more attractive investment opportunities [54] Question: Optimal mix between liquid investments and private credit loans - Management stated that they do not have a prescribed mix but will seek the best opportunities available at any given time [56] Question: Exposure to tariffs and potential impacts - Management assessed that tariff exposure in the portfolio is minimal, with a low single-digit percentage across the portfolio [65][66]